Invited Review

Differential signaling through the T cell receptor: from biochemistry to transplantation tolerance

J. Madrenas and A.I. Lazarovits
The John P. Robarts Research Institute, and the Departments of Microbiology and Immunology and Medicine, The University of Western Ontario, London, Ontario, Canada

Summary. Recent advances in our understanding of the structural nature of T cell activation and signal transduction from the T cell receptor for antigen make possible the development of new tolerogenic strategies. Here, we summarize the evidence supporting a critical role for the co-receptor molecule (CD4 or CD8) and CD45 in determining the pattern of T cell receptor-mediated signaling. The consequences of this differential signaling can range from T cell proliferation and cytokine production to the establishment of a state of proliferative unresponsiveness known as T cell anergy. Inducing T cell anergy can be an alternative approach for the establishment of transplantation tolerance.

Key words: Signal transduction, Transplantation, T cell tolerance

Introduction

T lymphocytes are critical regulatory and effector cells of the adaptive immune response. Their function becomes apparent upon clone-specific activation following engagement of their surface receptor for antigen (TCR) with its natural ligand, a transmembrane complex formed by an immunogenic peptide bound to the groove of a major histocompatibility complex (MHC) molecule on the surface of an antigen-presenting cell (APC). Full T cell activation results in activation of transcription of multiples genes, including the interleukin-2 (IL-2) gene. This will result in IL-2 production which will ultimately lead to proliferation and differentiation of the T cells into effector cells.

The signals transduced upon specific interaction between the TCR and its ligand, grouped as ‘signal 1’, are not sufficient for full T cell activation. Additional signals, known altogether as costimulation or ‘signal 2’, are required and delivered by different receptors on the surface of the T cell upon engagement with their ligands (e.g. CD28-CD80, CD28-CD86, adhesion molecule-ligand interactions or cytokine-cytokine receptor interactions) (Schwartz, 1990). This two-signal paradigm for T cell activation has been very useful in providing a framework to understand T cell activation and to dissect the functional contribution of recognition and costimulatory signals.

A prediction of the two-signal model is that either one of the two signals alone will not induce T cell proliferation and differentiation, and this is indeed the case. However, a remarkable observation made during studies on the requirements for T cell activation was that TCR engagement is not ignored by the T cell in the absence of costimulation but results in a state of proliferative unresponsiveness known as T cell anergy. Inducing T cell anergy can be an alternative approach for the establishment of transplantation tolerance.

Key words: Signal transduction, Transplantation, T cell tolerance
primary T cells from different in vivo models of tolerance or disease and re-examine the involvement of anergy as a mechanism. Second, the demonstration that the TCR complex can signal in different patterns, some of these resulting in the induction of T cell anergy, has revived the interest for in vivo conditions in which this may occur and for strategies that could result in the induction of T cell anergy (Sloan-Lancaster and Allen, 1995; Madrenas and Germain, 1996).

In this paper, we will review the evidence implying that the TCR is a versatile signaling complex. As such, the TCR is capable of transducing in a variety of signaling patterns that will result in the development of different effector T cell responses, ranging from T cell pro-liferation and cytokine production to T cell anergy. We will then discuss the current information on the structural basis for this versatility that translates into differential signaling from the TCR. In particular, we will focus on the role that the co-receptor molecule (CD4 or CD8), and CD45 may have in differential signaling from the TCR. Finally, we will examine how this information may impact on the development of new therapeutic strategies for the induction of anergy-based T cell unresponsiveness.

T-cell signaling and transplant tolerance

The TCR is a molecular complex formed by a clonotypic αβ or γδ heterodimer non-covalently associated to four non-polymorphic CD3 chains (two CD3 ε, one CD3 γ, and one CD3 δ), and two TCR-ζ chains or its variant η chain. The αβ or γδ heterodimer is responsible for antigen recognition while the CD3-TCR-ζ chains are responsible for signal transduction. The fine stoichiometry of the TCR complex in basal conditions is not known. Recent crystallographic data on a TCR engaging a peptide:MHC molecule indicates that this interaction involves multiple regions of the membrane-distal domains of the TCR and requires an appropriate orientation of TCR engagement as well as congruency between the receptor and its ligand (Garboczi et al., 1996; Garcia et al., 1996a). Kinetic data using soluble TCR and its peptide: MHC molecule ligand indicate that the affinity of this interaction is low, with a fast dissociation rate (Matsui et al., 1991, 1994; Weber et al., 1992; Corr et al., 1994; Alam et al., 1996; Lyons et al., 1996).

The earliest detectable event upon T cell activation from recognition of specific peptide:MHC molecule complexes is tyrosine phosphorylation at YxxL(I)x(6−g)Yxx(L/I) motifs, known as immune receptor tyrosine-based activation motifs (ITAMs) (reviewed in (Wange and Samelson, 1996)). These motifs are located in the cytoplasmic tails of the TCR ζ chains (3 in each chain) and CD3 γ, δ, and ε chains (1 in each chain). Phosphorylation of the tyrosines in these motifs is the primary function of two src-related protein tyrosine kinases (PTK): p56lck and p59fyn. These kinases have distinct ways to associate with the activating complex: most lck is primarily associated to the C terminus of the co-receptor (CD4 or CD8) molecules (Veillette et al., 1988), while fyn can associate directly to the TCR (Samelson et al., 1990). The specific contribution of each one of these src-kinases in TCR-mediated signaling in developing and mature T cells is still controversial. During T cell development both src-kinases are essential (Groves et al., 1996; van Oers et al., 1996), although the defect caused by deletion of the lck gene is more intense than the corresponding one from fyn knock-out mice (Appleby et al., 1992; Molina et al., 1992). In mature αβ T cells, lck seems to play an essential role although fyn may be required in a subset of mature T cells. Through the action of either one or both of them, the tyrosine residues on the ITAMs are phosphorylated and serve as a recruitment signal for cytosolic PTKs.

Tyrosine phosphorylation of ITAMS is representative of a general mechanism for the recruitment of signaling molecules. These molecules often contain conserved domains that function to colocalize other molecules (usually kinases) with their substrates or with adapters that will bind to the substrates (Pawson, 1995). The following types of domains have been so far identified: SH2, PTB, SH3, PH, WW, PDZ, and LIM. These domains are involved in the recognition of tyrosine phosphorylated motifs (SH2, PTB, and LIM), of proline-rich regions (SH3 and WW), interaction with phospholipids (PH), and valine-C terminus motifs (PDZ). This modularity in the signaling molecules increases their versatility, and contributes to the specificity of the signaling cascades in which they may be involved.

One of the early tyrosine kinases recruited to the TCR by tyrosine phosphorylation of the TCR subunits is ZAP-70. This PTK plays a critical role in TCR-mediated signaling as demonstrated by the severe defect in T cell activation observed in ZAP-70 knock out mice and in patients homozygous for mutations of the ZAP-70 gene (Chan et al., 1992, 1994; Arpaia et al., 1994; Elder et al., 1994; Negishi et al., 1995). Upon recruitment of ZAP-70 to the TCR, this PTK is tyrosine phosphorylated and activated. Only two substrates of ZAP-70 have been clearly identified so far: SLP-76, and perhaps HSF1 (reviewed in Wange and Samelson, 1996). An alternative group of PTKs that may be involved in TCR-mediated signaling is the Itk/Tec group, as indicated by the severe deficit in T cell development and function in Itk knock out mice (Liao and Litman, 1995).

As a result of activation of these kinases, there is triggering of a cascade of downstream events involving at least three different signal transduction pathways. One pathway involves the activation of phospholipase C γ 1 and subsequent hydrolysis of inositol phosphates leading to the generation of IP3 and DAG. IP3 will in turn induce Ca++ influx and DAG will activate protein kinase C. Another is the p21 ras-MAPK-MAPKK pathway that will lead to the translocation of kinases to the nucleus where they will ultimately phosphorylate and activate transcription factors. The third pathway, partially characterized, includes the activation of PI3 kinase.
What activates the src-related PTKs? Structural characterization of the src family PTKs has shown the presence of a tyrosine residue (505) in their C terminus that plays a negative regulatory role on the kinase activity of the PTK when phosphorylated. From a functional point of view, activation of the kinase function requires dephosphorylation of such tyrosine residues, as indicated by constitutive activation of Ick when this tyrosine residue is mutated into phenylalanine (reviewed in Peri and Veillette, 1994; Zenner et al., 1995). Thus, activation of the src-family of PTKs requires the activity of a phosphatase. An attractive candidate for this role is CD45.

CD45 is a transmembrane tyrosine phosphatase expressed by leukocytes (Trowbridge and Thomas, 1994; Okumura and Thomas, 1995). The ligand(s) of CD45 on the APC is still an enigma. A group has reported that CD45 can interact with the B cell specific receptor CD22 (Stamenkovic et al., 1991). The heavy glycosylation of the N terminus of CD45 also suggests that this phosphatase can interact with many molecules through carbohydrate-mediated contact. At least four different isoforms have been described on T cells, as a result of alternative splicing of the RNA coding for the CD45 A, B, or C exons. These isoforms differ in their N terminus and are known as CD45RO, CD45RA, CD45RB, and CD45RC. The distinct functions of these different isoforms are currently unknown. However, it is possible that these different isoforms may have different abilities to transduce signals. As mentioned above, CD45 is able to dephosphorylate the src-family Ick and fyn kinases on the negative regulatory 505 tyrosine. The CD45 molecule contains two phosphatase domains in the intracellular region of the molecule. The phosphatase activity seems to be concentrated though on the first of these domains. In the absence of CD45 expression, T cells lose the ability to become activated through the TCR. The in vivo relevance of this finding is shown by the severe defect in thymocyte development seen in mice unable to express CD45.

CD45 phosphatase activity can be increased by phosphorylation on tyrosine and serine residues located on the second phosphatase domain of CD45. Interestingly, the p50<sub>csk</sub> tyrosine kinase, that negatively regulates TCR-mediated signaling (Chow et al., 1993) probably by tyrosine phosphorylation of p56<sub>ICK</sub> (Bergman et al., 1992), also phosphorylates CD45 causing an increase in its phosphatase activity (Mustelin, 1994). In addition, CD7 also phosphorylates CD45 on tyrosine residues (Lazarovits et al., 1994). This is just a good example of regulation of TCR-mediated signaling by phosphatases, a whole new area starting to be...
unraveled (Marengere et al., 1996; Pani et al., 1996; Plas et al., 1996).

**Evidence for differential signaling from the TCR**

Until recently, the TCR was considered a transducing complex with an all-or-none function depending on occupancy of the receptor above an affinity threshold. According to this simple model, signals transduced by the TCR were qualitatively identical and could only be quantitatively regulated by manipulation of the level of occupancy of the receptor. Several lines of evidence have recently challenged this view and have provided strong support to the concept that the receptor is capable of sensing fine differences in the quality of the ligand that will result in differential signaling patterns.

The first piece of evidence came from observations of split function or inhibitory effect upon engagement of the TCR with variant ligands (reviewed in Evavold et al., 1993; Germain et al., 1995; Jameson and Bevan, 1995). These variant TCR ligands were obtained after slight modifications of the peptide or the MHC molecule at the secondary TCR contact residues. Depending on the system, CD4+ or CD8+ T cells lost the ability to proliferate but still up-regulated some cell surface receptors and were able to produce some cytokines but not others, or lost some effector function such as cytotoxicity. In addition, the interaction between a variant TCR ligand and the TCR can induce activation of the APC and subsequent activation of some functions of the T cell (Matsuoka et al., 1996). Using the pharmacological nomenclature for different types of receptor ligands, these altered peptide:MHC ligands have been classified as partial agonists or antagonists depending on whether they induce only some functions but not others or they are capable of inhibiting activation by agonist ligands.

A critical observation made during these studies was that some partial agonist ligands were capable of inducing T cell anergy in conditions in which co-stimulation was not limiting (Sloan-Lancaster et al., 1993). The cellular characteristics of T cell anergy induced by variant TCR ligands are indistinguishable from T cell anergy induced by TCR engagement in the absence of co-stimulation: it is cyclosporin-sensitive, implying a Ca++-dependent pathway, and can be blocked by the induction of T cell proliferation with exogenous IL-2 (Sloan-Lancaster et al., 1993; Madrenas et al., 1996).

The plethora of biological effects of variant TCR ligands was soon followed by biochemical evidence of differential signaling induced by these ligands. As expected, most changes occur during the early stages of TCR-mediated signaling at the level of tyrosine phosphorylation of TCR subunits. Different signaling patterns are observed when tyrosine phosphorylation of TCR subunits is examined after engagement of the TCR with agonist or partial agonist/antagonist ligands (Fig. 1) (Sloan-Lancaster et al., 1994; Madrenas et al., 1995). Agonists of the TCR induce the appearance of two forms of tyrosine phosphorylated TCR ζ chain, and tyrosine phosphorylation of CD3 ε. In contrast, TCR partial agonists and antagonists predominantly induce the appearance of the p21 form of phospho-TCR ζ, with much less or no phospho-p23 TCR ζ and very little or no phospho-ε. This differential pattern of tyrosine phosphorylation of TCR subunits translates into differential downstream activation. Specifically, TCR agonists induce recruitment, tyrosine phosphorylation, and activation of ZAP-70. In contrast, TCR partial agonists and antagonists induce the recruitment of ZAP-70 to the TCR complex but fail to induce tyrosine phosphorylation and activation of this kinase.

The differential downstream effects induced by partial agonists of the TCR is consistent with the activation of some signaling pathways but not others. Fine characterization of these pathways is elusive. Variant TCR ligands can induce acid release (a measure of cell activation through different pathways), cytosolic Ca++ fluxes, and signaling through the calcineurin-dependent pathway as indicated by the sensitivity to cyclosporin of their ability to induce T cell anergy (Sloan-Lancaster et al., 1993, 1996; Rabinowitz et al., 1996a,b). However, each of these responses have some distinctive features. For example, the levels of cytosolic Ca++ responses induced by TCR partial agonists are lower and shorter than those seen with agonists ligands (Sloan-Lancaster et al., 1996). In addition, it has not been possible to demonstrate increases in the generation of IP3 by variant TCR ligands (Ruppert et al., 1993; Raciotto et al., 1996), raising the possibility that (if the sensitivity of IP3 detection is similar to that of Ca++ influxes) there are IP3-independent pathways of Ca++ release.

What is the determining factor for differential TCR signaling upon engagement with variant ligands? Recent evidence indicates that the TCR partial agonist and antagonist ligands examined so far have lower affinities for soluble TCR than the agonist ligands (Alam et al., 1996; Kersh and Allen, 1996; Lyons et al., 1996). This difference becomes more striking when one considers the much faster dissociation rates observed for partial agonists and antagonists (Alam et al., 1996; Lyons et al., 1996). In the context of these data, it is likely that the mechanism of action of these variant TCR ligands can be explained by an affinity model (McKeithan, 1995; Madrenas and Germain, 1996). According to this model, the affinity of the TCR for its ligands determines the length of engagement of the receptor. The time of engagement will determine the assembly of the appropriate signaling machinery for full signaling to occur. Lower affinities will correlate with shorter times of engagement and partial signaling with induction of some early signals (e.g. appearance of phospho-p21 TCR ζ form and recruitment of ZAP-70) but not others (e.g. tyrosine phosphorylation and activation of ZAP-70) (Beeson et al., 1996). This model is also consistent with the findings of McConnel's group pointing to a
hierarchy in T cell responses that would start with TCR ζ phosphorylation and proceed to partial Ca++ fluxes, acid release, full intracellular Ca++ release, and T cell proliferation depending on the duration or intensity of TCR engagement (Rabinowitz et al., 1996a,b). It is not known whether these responses would be causally related or would be occurring in parallel. If the latter is true, then one may claim differential amplification of the different pathways to proximal responses, and preservation of some responses but not others.

We cannot ignore that the measurement of TCR affinities was done in solution, using soluble components, and that only two specific TCR partial agonist-antagonist ligand systems have been examined. Therefore, it may be not entirely representative of TCR:peptide:MHC molecule interactions occurring in vivo between T cell and APC and with participation of multiple accessory molecules, or of other partial agonist-antagonist systems. In the latter cases, the differences in affinities and dissociation rates may be minor, and one may have to claim other models to explain their mechanism of action e.g. allosteric or architectural interference of TCR signaling induced by the variant TCR ligand (reviewed in Madrenas and Germain, 1996).

Involvement of the CD4/CD8 coreceptor molecule in differential signaling from the TCR

Most mature T cells express either CD4 or CD8 molecules on their surface. These molecules play a co-receptor function by binding respectively non-polymorphic regions of the class II or class I MHC molecules interacting with the TCR. The co-receptor function in T cell activation is twofold. On one hand, they are involved in the stabilization of the TCR:peptide:MHC molecule complex, and in this way contribute to the overall affinity of the TCR interaction with the peptide:MHC molecule complex (Luescher et al., 1995: Garcia et al., 1996b). On the other hand, they participate in the early signaling process by their non-covalent association with the src-kinase lck (Veillette et al., 1988). Given these two features of the co-receptor function, it is plausible to suggest that the co-receptor molecule plays a crucial role in differential signaling by variant TCR ligands by linking the affinity of the TCR:ligand interaction with the activation of intracellular signaling pathways. The evidence currently available supports such a role.

The level of co-receptor expression can determine the type of T cell response to specific variant TCR ligands. Increased CD4 expression can convert an antagonist ligand into an agonist ligand, and a null ligand into an antagonist ligand (Vidal et al., 1996). In the context of the kinetic model of differential signaling, one can explain these findings by claiming that the increase in CD4 expression is associated with more rapid co-localization of the CD4 molecules with the engaged TCR, allowing for TCR-CD4 co-engagement with peptide:MHC molecule, and the formation of more stable activating complexes.

The role of co-receptor molecules in determining the pattern of T cell responses to peptide:MHC molecule complexes can also be evidenced using blocking monoclonal antibodies against CD4 or CD8. For example, blockage of CD8 function with monoclonal antibodies converted a poor antagonist into a very powerful antagonist (Jameson et al., 1994), and antibodies against CD4 converted a partial agonist ligand into an antagonist ligand (Mannie et al., 1995). We have recently demonstrated that blockage of CD4 function with monoclonal antibodies or by mutation of the CD4 binding site on the MHC class II molecule can lead to the conversion of an agonist response into a partial agonist response, even though the ligand is not altered (Madrenas et al., 1997). This response is characterized by a distinct pattern of signaling from the TCR with predominant appearance of the p21 tyrosine phosphorylated form of TCR ζ but not of phospho23 or CD3-ε and by failure to activate ZAP-70. In addition, as described for responses to TCR partial agonists, TCR engagement with agonist ligands in the presence of CD4 blockage caused a split in cytokine production, with inhibition of IL-2 production but relative preservation of IL-3 production, and the induction of T cell anergy. Similar results were obtained using heterofunctional antibodies against CD3 alone compared with CD3 and CD4 antibodies. Thus, while TCR-CD4 co-engagement with peptide:MHC molecule complex determines an agonist-type of response, failure to induce such co-engagement determines a partial agonist-type of response. These conclusions are consistent with recent data demonstrating the quantitative contribution of the co-receptor molecule to the stabilization of TCR:peptide:MHC molecule (Garcia et al., 1996b).

The link between the efficiency of TCR-CD4 co-engagement and the TCR-dependent signaling pattern most likely involves changes in the activity of lck. It has been recently reported that the kinase activity of the CD4-associated fraction of lck is increased upon TCR engagement with antagonist ligands, similar to what is seen after TCR engagement with agonist ligands (Racioppi et al., 1996). The association of antagonist-induced increase in lck kinase activity with decreased antigenism in the presence of monoclonal antibodies against CD4 has led to the proposal that the CD4-associated fraction of lck may have a negative signaling effect on the TCR-mediated activation process. This would not be occurring when lck is sequestered with the anti-CD4 monoclonal antibodies. Alternatively, one could claim that the antibodies against CD4 may further decrease the affinity of interaction between the TCR and the antagonist ligand or may have some agonistic effects upon activation of lck and subsequent activation through the TCR in agonist mode. This alternative hypothesis is supported by data demonstrating that decreased expression and activity of lck leads to partial TCR-mediated signaling that translates into severe defect in T cell proliferation but preserves cytokine production (Al-
Ramadi et al., 1996).

The information presented above provides us with a new base to evaluate the evidence supporting a therapeutic window for the use of monoclonal antibodies against CD4 and/or CD8. It is well documented that, in rodent models of autoimmunity and transplantation tolerance, monoclonal antibodies against CD4 and CD8 can induce a long lasting state of antigen-specific T cell unresponsiveness, and we would claim that this is due to the induction of T cell anergy by differential TCR-mediated signaling (Shizuru et al., 1992; Alters et al., 1993; Waldmann and Cobbold, 1993). Experiments trying to address the underlying mechanism of this phenomenon are currently underway.

**Contribution of CD45 in differential signaling from the TCR**

As previously discussed, CD45 plays a crucial role in lymphocyte signal transduction. Thus, it is important to examine the effects blockade of CD45 on T cell function. Our interest has initially focused on the CD45RB isoform of this molecule. We have recently reported that mice receiving a kidney allograft and treated with a monoclonal antibody against the CD45RB molecule (MB23G2) have a significant prolongation of graft survival to levels comparable to the isografted mice (Lazarovits et al., 1996). Remarkably, a different monoclonal antibody against CD45RB (MB4B4) was no better than the vehicle alone at preventing rejection. Using syngeneic and allogeneic skin transplants, we were able to demonstrate that antigen specific tolerance had been induced by the effective antibody against CD45RB. In addition, the effective antibody against CD45RB was useful to reverse kidney allograft rejection.

The mechanism of action of the effective anti-CD45RB antibody is still unclear. Several possibilities may be considered. First, the CD45RB monoclonal antibody may interfere with TCR-mediated signal transduction perhaps by steric hinderance, or by preventing interaction of the extracellular domain of the CD45RB protein with its natural ligand. Second, the CD45RB monoclonal antibody could physically interfere with the interaction of CD3-TCR with the allogeneic histocompatibility molecule since CD45 is known to be physically linked with CD3-TCR and CD7 (Lazarovits et al., 1994). These possibilities are not mutually exclusive. With these possibilities in mind and with the knowledge that CD45 is a protein tyrosine phosphatase (Trowbridge and Thomas, 1994), we designed experiments to test the hypothesis that the mechanism of induction of tolerance by CD45RB antibody is related to an alteration in tyrosine phosphorylation of T cell substrates necessary for signal transduction to occur.

![MB23G2 monoclonal antibody augments the tyrosine phosphorylation of phospholipase C γ-1.](image-url)

**Fig. 2.** MB23G2 monoclonal antibody augments the tyrosine phosphorylation of phospholipase C γ-1. The A1.1 T cell hybridoma was stimulated with anti-CD3 ε mAb 2C11 for 5 minutes at 37 °C at a concentration of 1 ug/ml (lanes 2 and 6), 2 μg/ml (lanes 3 and 7), 5 μg/ml (lanes 4 and 8), 10 μg/ml (lanes 5 and 9), or they were left in the absence of 2C11 stimulation (lanes 1 and 10). For lanes 6 to 10, the cells were incubated in the presence of 50 μg/ml of MB23G2. The cells were lysed and lysates underwent immunoprecipitation with phosphotyrosine mAb PY72 and immunoblotted with antibodies to PLC γ-1 (panel A). Location of PLC γ-1 is indicated by the arrow. Panel B represents measurements obtained by densitometry from the blot in panel A. The histograms are ratios of adjusted volumes of MB23G2 and 2C11 coinubcation: 2C11 alone or no 2C11 as the case may be.
As shown in figure 2, in the presence of the effective MB23G2 monoclonal antibody, there is an increase in tyrosine phosphorylation of phospholipase C (PLC) γ-1. The ineffective antibody MB4B4 had no effect on tyrosine phosphorylation of PLC γ-1. It is interesting to point out that anergic T cells have an increase in the levels of tyrosine phosphorylation of PLC γ-1 (Gajewski et al., 1994) as well as of p59fyn, with increased functional activity of p59fyn (Quill et al., 1992; Bhandoola et al., 1993; Cho et al., 1993). In addition, anergic T cells show a decrease in tyrosine phosphorylation of p56lck and ZAP-70 with decreased activity of these PTKs, probably as a result of decreased and/or altered TCR-mediated signaling leading to decreased tyrosine phosphorylation of certain CD3 polypeptides (Quill et al., 1992; Bhandoola et al., 1993; Cho et al., 1993; Migita et al., 1995). Our data are provocative, and suggest that certain stimuli delivered through CD45RB induce tolerance by rendering the allogeneic T cells anergic.

Although the relationship between the changes in tyrosine phosphorylation induced by the MB23G2 monoclonal antibody against CD45RB and the induction of long-term graft acceptance is not known, it is reasonable to speculate that the latter is the result of a partial T cell activation induced by this antibody and similar to that caused by some TCR partial agonists. Given the upstream role that CD45 plays on activation of Ick, one could argue that this may occur by causing co-sequestration of CD45 and CD4 or any other molecule critical for full TCR-mediated signaling (Lazarovits et al., 1992, 1994), and leading to a partial activation of the CD4-associated fraction of this kinase. Alternatively, one could claim that the antibody blocks the phosphatase activity of CD45 or any other function that may regulate TCR-mediated signaling. As a result of partial T cell activation, T cells become anergic. A major issue that needs to be addressed is why this effect is observed with this particular antibody against the CD45RB isofrom and it is not shared by another antibody against the same isofrom.

From biochemistry to transplantation tolerance

An alternative vision of TCR-mediated signaling is emerging. This involves a versatile signal transduction machine, able to sense small changes in the quality of the ligand, and translating those changes in differential activation of T cells. This results in different responses ranging from full T cell activation with cell proliferation, and cytokine production, to inhibition of on-going responses, to T cell anergy. This versatility of the TCR may be operational in physiological events such as during development of the T cell repertoire in the thymus through positive and negative selection, or in the maintenance of peripheral T cell tolerance.

The current challenge is to apply this new knowledge in therapeutically feasible strategies. Structural information from dissection of TCR epitopes implies that there are some general principles for peptide binding to MHC molecules (Ljunggren and Thorpe, 1996; Nelson et al., 1996) and these may be valid for the generation of variant TCR ligands with partial agonist and antagonist properties in high frequency (as high as 50% of all substitutions in a particular residue (Chen et al., 1996; Hsu et al., 1996)). However, it is still unclear how restrictive TCR recognition will be as to limit the validity in polyclonal or even in oligoclonal responses. In this sense, the knowledge coming from studies manipulating the formation of activating complexes with monoclonal antibodies against CD4, CD8, or CD45 may be more applicable in the short term to reproduce the effects seen with engagement of the TCR with variant TCR ligands in vivo situations. The establishment of reliable and reproducible protocols to attain this outcome will certainly be a major achievement.

Acknowledgments. We wish to thank our colleagues in our laboratories, at the Robarts Research Institute, in the Multi-Organ Transplant Service, and in our departments for helpful comments and criticisms that have been very useful in the development of the ideas expressed in this review. We also acknowledge the many contributions of scientists whose work has not been referenced due to space limitations. Research presented in this review paper has been funded by the Kidney Foundation of Canada, the Medical Research Council of Canada, and the Multi-Organ Transplant Service of the London Health Sciences Centre at the University of Western Ontario.

References


T-cell signaling and transplant tolerance


Matsui K., Boniface J.J., Reay P.A., Schild H., Fazekas de St-Groth B.
T-cell signaling and transplant tolerance


